Digital slide box showing 11 cases (SCLC, normal pancreas, carcinoid, NSCLC) stained with VENTANA INSM1 (SP493) Rabbit Monoclonal Primary Antibody, with annotations for H&E, Negative Reagent Control, and immunohistochemistry stained slides.
This series of videos is provided as a resource for individuals in countries where VENTANA PD-L1 (SP263) Assay is approved for use for non-small cell lung cancer (NSCLC).
Please refer to the respective drug labeling for clinical recommendations pertaining to PD-L1 expression.
These videos feature Roche Tissue Diagnostics Pathologist, Dr. Dorothy Hayden, and are intended to be a refresher for pathologists and laboratories on VENTANA PD-L1 (SP263) Assay in NSCLC. Module 1 is a PD-L1 and PD-L1 (SP263) assay overview , Module 2 discusses evaluation guidance for PD-L1 (SP263) assay in NSCLC, and Module 3 is a PD-L1 (SP263) Guided Digital NSCLC Case Review
Virtual Training on assessing PD-L1 in non-small cell lung cancer using the VENTANA PD-L1 (SP142) assay.
Virtual Training on assessing PD-L1 in non-small cell lung cancer using the VENTANA PD-L1 (SP263) assay.